Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04

AUTHORS

O. Abdel-Rahman

ABSTRACT

BACKGROUND: The current analysis aims to provide an evaluation of the impact of diabetes mellitus (DM) on the efficacy and safety of first-line FOLFOX chemotherapy for patients with metastatic colorectal cancer (mCRC). METHODS: This is a pooled analysis of the comparator arms of two clinical trials (NCT00272051; NCT00305188) which evaluated first-line FOLFOX chemotherapy for patients with mCRC. The overall survival and progression-free survival according to patient subsets (non-diabetic and diabetic patients) were assessed through Kaplan-Meier analysis and log-rank testing. Propensity score matching was additionally conducted to account for heterogeneity in baseline characteristics of different subsets of patients. RESULTS: A total of 756 patients were enrolled in the current analysis; of which 64 patients have pre-existing DM while 692 patients were non-diabetic. Through Kaplan-Meier analysis, no evidence for overall or progression-free survival difference was found among the two patient subsets (P = 0.501; P = 0.960, respectively). Moreover, metformin treatment does not affect overall or progression-free survival among diabetic patients (P = 0.598; P = 0.748, respectively). Repetition of overall and progression-free survival assessment following propensity score matching does not reveal any differences. Comparing diabetic to non-diabetic patients, there were no differences between the two groups in terms of acute oxaliplatin-induced neurological symptoms including cold-induced dysthesia (P = 0.600), laryngeal dysthesia (P = 0.707), jaw pain (P = 0.743) or muscle pain (P = 0.506). Moreover, no difference was seen between the two groups in terms of the incidence of long-term oxaliplatin-induced paresthesia (P = 0.107), highest grade of paresthesia (P = 0.498) or rates of recovery from paresthesia (P = 0.268). Diabetic patients have, however, a shorter time to develop oxaliplatin-induced paresthesia (P = 0.024). CONCLUSION: DM does not seem to affect overall or progression-free survival of mCRC patients treated with first-line FOLFOX chemotherapy. Moreover, DM does not influence the incidence or severity of oxaliplatin-induced paresthesia in those patients while it might lead to a shorter time to develop oxaliplatin-induced paresthesia compared to non-diabetic patients. More... »

PAGES

512-518

References to SciGraph publications

  • 2013. Adiposity and Diabetes in Breast and Prostate Cancer in ADIPOSE TISSUE AND CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12094-018-1939-8

    DOI

    http://dx.doi.org/10.1007/s12094-018-1939-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1106624072

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30182209


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Alberta Health Services", 
              "id": "https://www.grid.ac/institutes/grid.413574.0", 
              "name": [
                "Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt", 
                "Department of Oncology, University of Calgary and Tom Baker Cancer Center, Calgary, AB, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Abdel-Rahman", 
            "givenName": "O.", 
            "id": "sg:person.0671451062.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671451062.54"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/978-1-4614-7660-3_3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004495044", 
              "https://doi.org/10.1007/978-1-4614-7660-3_3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2337/dc10-0666", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019474927"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.ejca.2013.04.032", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022308051"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.diabet.2013.12.007", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023428920"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/annonc/mdp509", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030065465"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/annonc/mds236", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034294500"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1593/tlo.13346", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045037477"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jop.0852002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045747505"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1055-9965.epi-16-0312", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1063224400"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1155/2017/5063239", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083764341"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1371/journal.pone.0176068", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084924457"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1053/j.gastro.2017.05.011", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1085405697"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1053/j.seminoncol.2017.10.004", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092183720"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/ijc.31311", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101034506"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/ijc.31311", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101034506"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1080/17474124.2018.1511426", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1106120492"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1080/17474124.2018.1511426", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1106120492"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-04", 
        "datePublishedReg": "2019-04-01", 
        "description": "BACKGROUND: The current analysis aims to provide an evaluation of the impact of diabetes mellitus (DM) on the efficacy and safety of first-line FOLFOX chemotherapy for patients with metastatic colorectal cancer (mCRC).\nMETHODS: This is a pooled analysis of the comparator arms of two clinical trials (NCT00272051; NCT00305188) which evaluated first-line FOLFOX chemotherapy for patients with mCRC. The overall survival and progression-free survival according to patient subsets (non-diabetic and diabetic patients) were assessed through Kaplan-Meier analysis and log-rank testing. Propensity score matching was additionally conducted to account for heterogeneity in baseline characteristics of different subsets of patients.\nRESULTS: A total of 756 patients were enrolled in the current analysis; of which 64 patients have pre-existing DM while 692 patients were non-diabetic. Through Kaplan-Meier analysis, no evidence for overall or progression-free survival difference was found among the two patient subsets (P\u2009=\u20090.501; P\u2009=\u20090.960, respectively). Moreover, metformin treatment does not affect overall or progression-free survival among diabetic patients (P\u2009=\u20090.598; P\u2009=\u20090.748, respectively). Repetition of overall and progression-free survival assessment following propensity score matching does not reveal any differences. Comparing diabetic to non-diabetic patients, there were no differences between the two groups in terms of acute oxaliplatin-induced neurological symptoms including cold-induced dysthesia (P\u2009=\u20090.600), laryngeal dysthesia (P\u2009=\u20090.707), jaw pain (P\u2009=\u20090.743) or muscle pain (P\u2009=\u20090.506). Moreover, no difference was seen between the two groups in terms of the incidence of long-term oxaliplatin-induced paresthesia (P\u2009=\u20090.107), highest grade of paresthesia (P\u2009=\u20090.498) or rates of recovery from paresthesia (P\u2009=\u20090.268). Diabetic patients have, however, a shorter time to develop oxaliplatin-induced paresthesia (P\u2009=\u20090.024).\nCONCLUSION: DM does not seem to affect overall or progression-free survival of mCRC patients treated with first-line FOLFOX chemotherapy. Moreover, DM does not influence the incidence or severity of oxaliplatin-induced paresthesia in those patients while it might lead to a shorter time to develop oxaliplatin-induced paresthesia compared to non-diabetic patients.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s12094-018-1939-8", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1035367", 
            "issn": [
              "1699-048X", 
              "1699-3055"
            ], 
            "name": "Clinical and Translational Oncology", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "21"
          }
        ], 
        "name": "Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies", 
        "pagination": "512-518", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "747f68310154f48429ec36dc7e65c56debb86658ac812d4df3058ce673e239d2"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30182209"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "101247119"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12094-018-1939-8"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1106624072"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12094-018-1939-8", 
          "https://app.dimensions.ai/details/publication/pub.1106624072"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T13:19", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78956_00000001.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://link.springer.com/10.1007%2Fs12094-018-1939-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12094-018-1939-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12094-018-1939-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12094-018-1939-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12094-018-1939-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    116 TRIPLES      21 PREDICATES      44 URIs      21 LITERALS      9 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12094-018-1939-8 schema:about anzsrc-for:11
    2 anzsrc-for:1112
    3 schema:author N6634e522ffc44ba1888db5c61cb0969c
    4 schema:citation sg:pub.10.1007/978-1-4614-7660-3_3
    5 https://doi.org/10.1002/ijc.31311
    6 https://doi.org/10.1016/j.diabet.2013.12.007
    7 https://doi.org/10.1016/j.ejca.2013.04.032
    8 https://doi.org/10.1053/j.gastro.2017.05.011
    9 https://doi.org/10.1053/j.seminoncol.2017.10.004
    10 https://doi.org/10.1080/17474124.2018.1511426
    11 https://doi.org/10.1093/annonc/mdp509
    12 https://doi.org/10.1093/annonc/mds236
    13 https://doi.org/10.1155/2017/5063239
    14 https://doi.org/10.1158/1055-9965.epi-16-0312
    15 https://doi.org/10.1200/jop.0852002
    16 https://doi.org/10.1371/journal.pone.0176068
    17 https://doi.org/10.1593/tlo.13346
    18 https://doi.org/10.2337/dc10-0666
    19 schema:datePublished 2019-04
    20 schema:datePublishedReg 2019-04-01
    21 schema:description BACKGROUND: The current analysis aims to provide an evaluation of the impact of diabetes mellitus (DM) on the efficacy and safety of first-line FOLFOX chemotherapy for patients with metastatic colorectal cancer (mCRC). METHODS: This is a pooled analysis of the comparator arms of two clinical trials (NCT00272051; NCT00305188) which evaluated first-line FOLFOX chemotherapy for patients with mCRC. The overall survival and progression-free survival according to patient subsets (non-diabetic and diabetic patients) were assessed through Kaplan-Meier analysis and log-rank testing. Propensity score matching was additionally conducted to account for heterogeneity in baseline characteristics of different subsets of patients. RESULTS: A total of 756 patients were enrolled in the current analysis; of which 64 patients have pre-existing DM while 692 patients were non-diabetic. Through Kaplan-Meier analysis, no evidence for overall or progression-free survival difference was found among the two patient subsets (P = 0.501; P = 0.960, respectively). Moreover, metformin treatment does not affect overall or progression-free survival among diabetic patients (P = 0.598; P = 0.748, respectively). Repetition of overall and progression-free survival assessment following propensity score matching does not reveal any differences. Comparing diabetic to non-diabetic patients, there were no differences between the two groups in terms of acute oxaliplatin-induced neurological symptoms including cold-induced dysthesia (P = 0.600), laryngeal dysthesia (P = 0.707), jaw pain (P = 0.743) or muscle pain (P = 0.506). Moreover, no difference was seen between the two groups in terms of the incidence of long-term oxaliplatin-induced paresthesia (P = 0.107), highest grade of paresthesia (P = 0.498) or rates of recovery from paresthesia (P = 0.268). Diabetic patients have, however, a shorter time to develop oxaliplatin-induced paresthesia (P = 0.024). CONCLUSION: DM does not seem to affect overall or progression-free survival of mCRC patients treated with first-line FOLFOX chemotherapy. Moreover, DM does not influence the incidence or severity of oxaliplatin-induced paresthesia in those patients while it might lead to a shorter time to develop oxaliplatin-induced paresthesia compared to non-diabetic patients.
    22 schema:genre research_article
    23 schema:inLanguage en
    24 schema:isAccessibleForFree false
    25 schema:isPartOf N16dbc88da889420a9b12358533832afc
    26 Nf7a23b6ed5c847f8b39019fbb884794d
    27 sg:journal.1035367
    28 schema:name Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies
    29 schema:pagination 512-518
    30 schema:productId N3982f619226c492c88728f53e5e8663a
    31 N59103f20e7c54b6895db3c675071a35f
    32 N623c5dc850144d3492dab70e4de49c5a
    33 N88d0357ae97d459883708cdf77133a6e
    34 Nbcbb658e2b8547fbabb2dbd544f1a16e
    35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106624072
    36 https://doi.org/10.1007/s12094-018-1939-8
    37 schema:sdDatePublished 2019-04-11T13:19
    38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    39 schema:sdPublisher Nfa1099da1b4944b4a57180447e6dc659
    40 schema:url https://link.springer.com/10.1007%2Fs12094-018-1939-8
    41 sgo:license sg:explorer/license/
    42 sgo:sdDataset articles
    43 rdf:type schema:ScholarlyArticle
    44 N16dbc88da889420a9b12358533832afc schema:volumeNumber 21
    45 rdf:type schema:PublicationVolume
    46 N3982f619226c492c88728f53e5e8663a schema:name nlm_unique_id
    47 schema:value 101247119
    48 rdf:type schema:PropertyValue
    49 N59103f20e7c54b6895db3c675071a35f schema:name readcube_id
    50 schema:value 747f68310154f48429ec36dc7e65c56debb86658ac812d4df3058ce673e239d2
    51 rdf:type schema:PropertyValue
    52 N623c5dc850144d3492dab70e4de49c5a schema:name doi
    53 schema:value 10.1007/s12094-018-1939-8
    54 rdf:type schema:PropertyValue
    55 N6634e522ffc44ba1888db5c61cb0969c rdf:first sg:person.0671451062.54
    56 rdf:rest rdf:nil
    57 N88d0357ae97d459883708cdf77133a6e schema:name pubmed_id
    58 schema:value 30182209
    59 rdf:type schema:PropertyValue
    60 Nbcbb658e2b8547fbabb2dbd544f1a16e schema:name dimensions_id
    61 schema:value pub.1106624072
    62 rdf:type schema:PropertyValue
    63 Nf7a23b6ed5c847f8b39019fbb884794d schema:issueNumber 4
    64 rdf:type schema:PublicationIssue
    65 Nfa1099da1b4944b4a57180447e6dc659 schema:name Springer Nature - SN SciGraph project
    66 rdf:type schema:Organization
    67 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    68 schema:name Medical and Health Sciences
    69 rdf:type schema:DefinedTerm
    70 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    71 schema:name Oncology and Carcinogenesis
    72 rdf:type schema:DefinedTerm
    73 sg:journal.1035367 schema:issn 1699-048X
    74 1699-3055
    75 schema:name Clinical and Translational Oncology
    76 rdf:type schema:Periodical
    77 sg:person.0671451062.54 schema:affiliation https://www.grid.ac/institutes/grid.413574.0
    78 schema:familyName Abdel-Rahman
    79 schema:givenName O.
    80 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671451062.54
    81 rdf:type schema:Person
    82 sg:pub.10.1007/978-1-4614-7660-3_3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004495044
    83 https://doi.org/10.1007/978-1-4614-7660-3_3
    84 rdf:type schema:CreativeWork
    85 https://doi.org/10.1002/ijc.31311 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101034506
    86 rdf:type schema:CreativeWork
    87 https://doi.org/10.1016/j.diabet.2013.12.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023428920
    88 rdf:type schema:CreativeWork
    89 https://doi.org/10.1016/j.ejca.2013.04.032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022308051
    90 rdf:type schema:CreativeWork
    91 https://doi.org/10.1053/j.gastro.2017.05.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085405697
    92 rdf:type schema:CreativeWork
    93 https://doi.org/10.1053/j.seminoncol.2017.10.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092183720
    94 rdf:type schema:CreativeWork
    95 https://doi.org/10.1080/17474124.2018.1511426 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106120492
    96 rdf:type schema:CreativeWork
    97 https://doi.org/10.1093/annonc/mdp509 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030065465
    98 rdf:type schema:CreativeWork
    99 https://doi.org/10.1093/annonc/mds236 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034294500
    100 rdf:type schema:CreativeWork
    101 https://doi.org/10.1155/2017/5063239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083764341
    102 rdf:type schema:CreativeWork
    103 https://doi.org/10.1158/1055-9965.epi-16-0312 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063224400
    104 rdf:type schema:CreativeWork
    105 https://doi.org/10.1200/jop.0852002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045747505
    106 rdf:type schema:CreativeWork
    107 https://doi.org/10.1371/journal.pone.0176068 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084924457
    108 rdf:type schema:CreativeWork
    109 https://doi.org/10.1593/tlo.13346 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045037477
    110 rdf:type schema:CreativeWork
    111 https://doi.org/10.2337/dc10-0666 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019474927
    112 rdf:type schema:CreativeWork
    113 https://www.grid.ac/institutes/grid.413574.0 schema:alternateName Alberta Health Services
    114 schema:name Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
    115 Department of Oncology, University of Calgary and Tom Baker Cancer Center, Calgary, AB, Canada
    116 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...